Literature DB >> 30443012

Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation.

Xinyu Wu1, Olivia Snir2, Douglas Rottmann1, Serena Wong1, Natalia Buza1, Pei Hui3.   

Abstract

Mismatch-repair deficiency testing plays a critical role in the identification of proband in Lynch Syndrome families and triaging patients with high stage or recurrent solid malignancies for check point inhibitor (Pembrolizumab) immunotherapy. We compared microsatellite shift patterns of microsatellite instability PCR analysis at 5 NCI recommended loci between microsatellite instability high endometrial carcinoma (n = 50) and microsatellite instability high colorectal cancer (n = 19). The endometrial cancer cohort included 45 endometrioid, 1 serous, and 4 clear cell carcinomas. Overall, 52% (26/50) of microsatellite instability high endometrial cancers showed minimal microsatellite shift (defined as a one to three nucleotide repeat shift at an involved locus) observed at least at one locus. Among microsatellite instability high endometrial cancers with minimal microsatellite shift, the frequencies at each involved locus were D2S123 (21/21, 100%), D17S250 (10/11, 89%), D5S346 (11/12, 92%), BAT25 (9/12, 80%), and BAT26 (8/21, 45%). Noticeably, 11 of the 26 cases (42%) showed only minimal shift. Among microsatellite instability high endometrial cancers with minimal microsatellite shift, 65% (17/26) had combined MLH1 and PMS2 loss, 8% (2/26) had combined MSH2 and MSH6 loss, 13% (3/26) had MSH6 loss and 15% (4/26) had loss of PMS2 by immunohistochemistry. In contrast, only 16% (3/19) had minimal microsatellite shift seen in colorectal cancer cohort with corresponding loss of MLH1/PMS2, MSH2/MSH6, or MSH6. Overall, 15% (7/50) of microsatellite instability high endometrial carcinomas showed isolated loss of MSH6 in contrast to 7% (1/15) seen in microsatellite instability high colorectal carcinomas. In conclusion, microsatellite instability high endometrial carcinomas have a significantly higher frequency of minimal microsatellite shift that coincides with a high percentage of combined loss of MLH1/PMS2. Microsatellite instability high endometrial cancers also have more frequent loss of MSH-6. Diagnostically, recognition of minimal microsatellite shift is crucial for accurate interpretation of microsatellite instability PCR data of endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30443012     DOI: 10.1038/s41379-018-0179-3

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients.

Authors:  Serena Wong; Pei Hui; Natalia Buza
Journal:  Mod Pathol       Date:  2020-01-13       Impact factor: 7.842

Review 2.  Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists.

Authors:  Anne M Mills; Tim N Bullock; Kari L Ring
Journal:  Mod Pathol       Date:  2021-09-07       Impact factor: 7.842

3.  Quantitative evaluation of MSI testing using NGS detects the imperceptible microsatellite changed caused by MSH6 deficiency.

Authors:  Gou Yamamoto; Takashi Takenoya; Akemi Takahashi; Yukiko Osanai; Miho Kakuta; Tetsuhiko Tachikawa; Takanori Washio; Masato Kamiyama; Michio Shiibashi; Shigeki Yamaguchi; Kiwamu Akagi
Journal:  Fam Cancer       Date:  2021-04       Impact factor: 2.375

Review 4.  The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review.

Authors:  Amelia Favier; Justine Varinot; Catherine Uzan; Alex Duval; Isabelle Brocheriou; Geoffroy Canlorbe
Journal:  Cancers (Basel)       Date:  2022-08-03       Impact factor: 6.575

5.  Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer.

Authors:  Franceska Dedeurwaerdere; Kathleen Bm Claes; Jo Van Dorpe; Isabelle Rottiers; Joni Van der Meulen; Joke Breyne; Koen Swaerts; Geert Martens
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

6.  Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer.

Authors:  Iiris Ukkola; Pirjo Nummela; Annukka Pasanen; Mia Kero; Anna Lepistö; Soili Kytölä; Ralf Bützow; Ari Ristimäki
Journal:  Virchows Arch       Date:  2021-03-23       Impact factor: 4.064

7.  IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.

Authors:  Timothy A Yap; Alberto Bessudo; Erika Hamilton; Jasgit Sachdev; Manish R Patel; Jordi Rodon; Lena Evilevitch; Meghan Duncan; Wei Guo; Sujatha Kumar; Sharon Lu; Bruce J Dezube; Nashat Gabrail
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.